Researchers propose new regulation mechanism linked to action of SirT6 on chromatin

Researchers from the Epigenetics and Cancer Biology Program of the Bellvitge Biomedical Research Institute (IDIBELL), led by Dr. Àlex Vaquero, have proposed a new regulation mechanism of the NF-κB pathway, which is associated with accelerated cellular aging, based on the analysis of the function of the SirT6 protein. The results of their work, published in Nature communications, indicate a double mechanism of inhibition of the pathway linked to the action of SirT6 on chromatin.

SirT6 is a sirtuin, an enzyme involved in the cellular response to stress. Specifically, SirT6 protects the stability of the genome and regulates the metabolic balance (homeostasis), and previous studies have already shown that its loss results in an accelerated aging phenotype associated with the hyperactivation of the NF-κB pathway, a family of transcription factors that regulate the cellular response to a wide variety of physiological conditions and that play a key role in cancer, inflammatory response and immune system.

Until now, several hypothesis stated that SirT6 kept the activation level of the NF-κB pathway low, blocking it specifically once it had received an activation signal. "In our study, however, we have identified a new mechanism associated with this regulation, whereby SirT6 not only controls NF-κB at the level of deactivation of specific repressor genes, but also controls the activation of a general repressor of the pathway", explains Dr. Àlex Vaquero, lead author of the study.

Thanks to several biochemical studies carried out in collaboration with the proteomics scientific-technical support unit of IDIBELL, researchers observed how SirT6 interacts with Suv39h1, an enzyme capable of adding methyl groups in a certain region of a histone (H3K9me3). SirT6 promotes the monoubiquitinization of Suv39h1 (Suv39h1mUb) catalyzed by the enzyme SKP2. This modification is of special interest, since it occurs in cysteine residues instead of lysine ones, something only previously observed in very few cases, and mostly in viral or peroxisome proteins. This is the first description of this modification in a nuclear factor in higher eukaryotes.

"The main function of ubiquitinization is to mark proteins - by adding many units of ubiquitin - for their degradation by the proteasome." In the published study, however, monoubiquitinization plays another role, since it interferes with the binding of Suv39h1 to chromatin and promotes that this enzyme "jumps off" the chromatin, activating the gene that acts as a general repressor of the NF-κB pathway", adds Dr. Vaquero.

Researchers have determined that this new SirT6-dependent mechanism of inactivation of the NF-κB pathway is largely related to cellular stress levels, but there are still unresolved questions. "This work opens a new path in the study of the functions of the ubiquitination in nuclear proteins, and suggests a regulatory landscape of these modifications much more complex than previously anticipated", concludes the IDIBELL researcher.

Comments

  1. Sherry Cryer Sherry Cryer United States says:

    Ubiquitination plays an very important roles in cellular processes including proteasomal degradation, endocytosis, DNA repair, cell cycle regulation, and gene expression. Creative Proteomics provides a broad range of technologies for ubiquitin research that enable quantification of protein amount and uniquitination modification.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Groundbreaking findings on TET2 pathway open doors for targeted blood cancer treatments